Publications
232
Citations
4,051
Est. group size
~40
Recurring co-author estimate
Active years
27
Publishing since 2000
Typically publishes in teams of ~10 · 25% small-team papers (≤3 authors) · across 17 venues
- Abstract B104: Research equity & survivor perspectives to enhance consent and trust: The respect recommendations for biorepository study enrollment practices
Cancer Epidemiology Biomarkers & Prevention · 2025
- MP04-20 SEXUAL AND URINARY FUNCTIONAL OUTCOMES FOLLOWING FOCAL THERAPY FOR PROSTATE CANCER
The Journal of Urology · 2025
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum
The Journal of Urology · 2025
- Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients
Future Oncology · 2025
- A systematic review of family history, race/ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening
Urologic Oncology Seminars and Original Investigations · 2024
- Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
Journal of Clinical Oncology · 2023
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
The Journal of Urology · 2023
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy
The Journal of Urology · 2023
- Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC).
Journal of Clinical Oncology · 2023
- Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
Journal of Clinical Oncology · 2022
- Spatial transcriptomic profiling of prostate cancer reveals zone specific androgen receptor signaling and immune infiltration
European Urology · 2022
- Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).
Journal of Clinical Oncology · 2022
- Biomarkers for prostate cancer detection and risk stratification
Therapeutic Advances in Urology · 2022
- Genomic Sequencing Should Be Part of the Standard of Care for Most Urologic Cancers: For
European Urology Focus · 2022
- Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).
Journal of Clinical Oncology · 2022
- The Journal of Urology×57
- Journal of Clinical Oncology×21
- European Urology×12
- Urology×9
- European Urology Supplements×7
- Lakshmi P. Kunju
Medicine · University of Michigan
- Udit Singhal
Medicine · University of Michigan
- Ganesh S. Palapattu
Medicine · University of Michigan
- Todd M. Morgan
Medicine · University of Michigan
- Rohit Mehra
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile